Research news round-up – Spring 2024
A round-up of the latest research into inherited retinal conditions - February 2024.
Search
Search results
Phase 3 clinical trial has been given approval by FDA
The FDA has given Ocugen permission to start their phase 3 gene therapy clinical trial for retinitis pigmentosa (RP).
News: Notice of the forthcoming Retina UK AGM – September 2024
Formal notice of the forthcoming Annual General Meeting in September 2024.
Applications invited for project grants and studentships
Retina UK invites applications for funding for innovative, high quality research projects investigating the causes and potential treatments for all forms of inherited retinal disease. We are particularly keen to receive proposals with demonstrable translational potential.
Notice of the forthcoming Retina UK AGM – July 2025
Formal notice of the forthcoming Annual General Meeting in July 2025.
Cell-ebrating the dosing of patients with jCell in a phase 2 clinical trial for RP
The latest research news from Retina UK.
Opus Genetics – the next BEST thing!
The latest research news from Retina UK.
Belite Bio – Phase 2/3 Trial for Adolescents with Stargardt disease
The latest research news piece from Retina UK.
Retina-on-a-chip: the tiny technology offering big hope for inherited sight loss
Researchers in the Netherlands are developing a “retina-on-a-chip” that mimics the key layers of the human retina, offering a powerful new way to study inherited retinal diseases (IRDs) and test potential treatments using human cells.
PDE6A gene therapy trial report: the importance of scientific learnings in an unsuccessful trial
Researchers from the University Hospital Tübingen in Germany recently announced that there were no signs of visual gains in an early-phase clinical trial of a PDE6A gene therapy for Retinitis Pigmentosa (RP).